Yeast strains and modified albumins
CA 2183241 C · Owner: Novozymes Delta Limited · Inventors: Kerry-Williams, Sean Martin; Gilbert, Sarah Catherine
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Albumin, for example human albu-, min, is expressed and secreted in yeast which has been mutated to lack the yeast aspartyl protease 3 (Yap3p) or its equivalent, thereby reducing the production of a 45kD albumin fragment. A further reduction is achieved by additionally deleting the Kex2p function. Alternatively, a modified albumin is prepared which is not susceptible to Yap3p cleavage, for example human albumin which is R410A, K413Q and, K414Q.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 1, 1995 and granted May 21, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 1, 2015.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 1, 2017.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.